Newest
-
EBYTE: 14 Years of Innovation — Building Full-Stack IoT Solutions
-
[Reaching New Heights] BOC Huitong Completes RMB 10 billion in Policy-Related Settlement Services; Phase III RMB 20 billion Entrusted Settlement Officially Launched
-
How Victor Hu Is Driving the Technological Evolution of Large-Scale AR Mapping and Spatial Intelligence Systems
-
Yilin Zhang debuts Myth 26 with AI Film Awards at Cannes, Marking First AI Feature Film Collaboration with Self-Conscious AI in Cinema History
I-Mab to Participate at the Truist Securities BioPharma Symposium
2024-10-29
I-Mab Biopharma
HaiPress

ROCKVILLE,Md.,Oct. 28,2024 --I-Mab (NASDAQ: IMAB),a US-based,global,biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7,2024.
Event Details
Meeting Date
Thursday,November 7,2024
Meetings
One-on-one and small group meetings:November 7,2024
Management
Participants
Sean Fu,PhD,MBA,Interim Chief Executive Officer (CEO)
Joe Skelton,Chief Financial Officer (CFO)
Phillip Dennis,MD,Chief Medical Officer (CMO)
Tyler Ehler,Senior Director,Investor Relations
For more information,please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedIn andX.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
